Amrita Krishnan

Amrita Krishnan at City of Hope is a myeloma specialist who has contributed to characterizing and managing cytokine release syndrome associated with bispecific antibody therapies in multiple myeloma. Her clinical expertise encompasses teclistamab, talquetamab, and other CD3-engaging bispecifics and the development of institutional CRS management protocols. She has contributed to bispecific antibody combination studies and worked on consensus guidelines for CRS grading and treatment in the bispecific era. Her work addresses immune-mediated toxicities and infectious complications specific to bispecific antibody-treated patients.